Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: J Endocrinol. 2018 Oct 16;239(2):253–265. doi: 10.1530/JOE-18-0382

IUGR impairs cardiomyocyte growth and maturation in fetal sheep

Sonnet S Jonker 1, Daniel Kamna 1, Dan Loturco 2, Jenai Kailey 2, Laura D Brown 2
PMCID: PMC6510659  NIHMSID: NIHMS1506395  PMID: 30143557

Abstract

Placental insufficiency causes intrauterine growth restriction (IUGR), a common complication of pregnancy. In skeletal muscle, IUGR reduces fetal myofibril size, reduces myoblast proliferation, and reduces expression of genes in cell cycle regulation clusters. The myocardium is striated like skeletal muscle, and IUGR also reduces cell cycle activity and maturation in cardiomyocytes, despite cardiac output preferentially directed to the coronary circulation. We hypothesized that cardiomyocyte growth restriction would be accompanied by similar changes in cell cycle regulation genes, and would reduce cardiomyocyte cell cycle activity, number, maturity and size. Pregnant ewes were housed in elevated ambient temperatures from ~40 to ~115 days of gestation (dGA) to produce placental insufficiency and IUGR; fetal hearts were studied at ~134 dGA. Hearts were biopsied for mRNA analysis and then dissociated into individual myocytes (Control n=8; IUGR n=15), or dissected (Control n=9; IUGR n=13). IUGR fetuses had low circulating insulin and insulin-like growth factor-1 (IGF-1), and high circulating cortisol. Bodies and hearts of IUGR fetuses were lighter than Controls. Cardiomyocytes of IUGR fetuses were smaller, less mature, less active in the cell cycle, and less numerous than Controls. Further, there was a pattern of down-regulation of cell cycle genes in IUGR ventricles. IUGR growth profiles in heart and skeletal muscle suggest similar regulation despite differences in blood and nutrient delivery prioritization. IGF-1 signaling is suggested as a mechanism regulating altered growth in IUGR striated muscle and a potential therapeutic candidate.

INTRODUCTION

Intrauterine growth restriction (IUGR) results from inadequate placental function limiting fetal nutrient delivery, impairing normal growth and development (Marconi and Paolini 2008). Infants affected by placental insufficiency redirect a greater proportion of oxygenated blood flow to the upper body, which enhances nutrient delivery to vital organs, including heart and brain, at the expense of other tissues such as skeletal muscle (Baschat and Hecher 2004; Bellotti, et al. 2004; Brown and Hay 2016). These fetal adaptations have life-long health implications, a phenomenon known as the developmental origins of health and disease first articulated by Barker and colleagues (Barker and Thornburg 2013; de Boo and Harding 2006; Fernandez-Twinn and Ozanne 2010). Placental restriction is associated with obesity, reduced lean body mass, insulin resistance, and cardiovascular disease in adulthood (Alexander, et al. 2015; Camm, et al. 2015; Fall 2011; Phillips, et al. 1994). Thus, while the heart and skeletal muscle are differently prioritized to receive nutrients during placental insufficiency, there are negative consequences for both following IUGR.

Hearts of fetal humans, sheep, rodents, and other mammals, grow by myocyte proliferation, terminal differentiation (which is associated with cellular enlargement, multinucleation, and cessation of proliferation), and enlargement of both proliferative and terminally differentiated myocytes (Burrell, et al. 2003; Clubb and Bishop 1984; Huttenbach, et al. 2001; Jonker, et al. 2015; Kim, et al. 1992; Zak 1974). Despite shunting shown to maintain coronary perfusion during IUGR in humans and sheep (Baschat and Hecher 2004; Bellotti et al. 2004; Tare, et al. 2014), hearts of fetal sheep with experimental placental insufficiency are reduced in weight (Bubb, et al. 2007; Louey, et al. 2007; Morrison, et al. 2007; Tare et al. 2014). IUGR is associated with less mature cardiomyocytes and reduced proliferation in near term fetal sheep, while disagreement persists as to whether the cells are smaller in fetal sheep and humans (Botting, et al. 2014; Bubb et al. 2007; Louey et al. 2007; Mayhew, et al. 1999; Morrison et al. 2007; Murotsuki, et al. 1997; Takahashi, et al. 1995).

Cardiac and skeletal muscle are both striated muscle, characterized by the organization of contractile proteins into sarcomeres, an abundance of mitochondria, and (in many species, including humans and sheep) multinucleation in maturity (Adler, et al. 1996). Unlike fetal cardiac muscle, in which working myocytes undergo cytokinesis, skeletal muscle grows by proliferation of myoblasts, and their subsequent differentiation and fusion to form multinucleated myotubes (Brown and Hay 2016). Also unlike the heart, skeletal muscle blood flow is reduced in IUGR, leading to a substantial reduction in oxygen and amino acid delivery (Poudel, et al. 2015; Rozance, et al. 2018); total mass and cross sectional area of hindlimb muscles are consequently reduced (Rozance et al. 2018; Soto, et al. 2017). Myoblasts capable of proliferating are maintained proportional to total number of nuclei, and even enhanced relative to myofiber number (indicating immaturity), but cell cycle activity in those myoblasts is reduced (Soto et al. 2017; Yates, et al. 2014). Pathway analysis in near-term IUGR skeletal muscle found decreased expression of clusters of genes related to proliferation and differentiation (Soto et al. 2017).

We hypothesized that in near-term fetuses with severe IUGR we would find ventricular cardiomyocyte immaturity, reduced proliferation, and suppression of intracellular growth regulatory pathways similar to those suppressed in skeletal muscle (Brown and Hay 2016; Soto et al. 2017). To test this hypothesis, we used a well-established sheep model of chronic, progressive placental insufficiency that results in severe IUGR (Limesand, et al. 2007; Regnault, et al. 2007; Thureen, et al. 1992). Placental insufficiency is initiated mid-gestation to reduce placental transfer of oxygen, amino acids and glucose similar to that experienced by the human IUGR fetus (Barry, et al. 2008; Bell, et al. 1987). We examined growth characteristics of cardiomyocytes and mRNA levels of genes that regulate the cardiomyocyte cell cycle.

MATERIALS AND METHODS

Animal model

Animal use was approved by the Institutional Animal Care and Use Committee of the University of Colorado, Denver.

Columbia-Rambouillet sheep (ovis aries) with singleton pregnancies were studied at the University of Colorado Perinatal Research Center as previously described (Soto et al. 2017). The fetuses in this study were included in previously published studies (Brown, et al. 2012; Culpepper, et al. 2016; Rozance et al. 2018). In brief, pregnant ewes were housed in environmental chambers with elevated ambient temperatures (40C for 12h; 35C for 12h) and 40% humidity from ~40 days gestation (dGA, term = 147 dGA) to ~115dGA to produce placental insufficiency and IUGR, after which they were housed in ambient temperatures and humidity (IUGR, n=15). Control ewes were housed in the same facility at ambient temperatures and normal humidity (Control, n=8). All sheep had ad libitum access to water. Maternal feed intake was matched on an absolute basis between sheep in the Control and IUGR groups (maternal weight-adjusted feed intake did not differ between groups).

Animals underwent surgery for fetal and maternal catheter placement as previously described, including catheterization of the fetal abdominal aorta (Soto et al. 2017). Briefly, ewes were fasted for 24h and water deprived for 12h prior to surgery. Diazepam (0.2mg/kg) and ketamine (20mg/kg) were administered intravenously, and then ewes were maintained throughout surgery on isoflurane inhalation anesthesia (2-4%). Maternal analgesia was provided with intramuscular banamine (1.1mg/kg). Surgical recovery was at least 5 days.

On the morning of tissue collection, fetal arterial blood was assayed for measurement of pH, partial pressure of CO2 (PCO2), partial pressure of O2 (PO2), O2 saturation, O2 content, hemoglobin, insulin, insulin-like growth factor 1 (IGF-1), norepinephrine and cortisol using biochemical methods previously described (Brown et al. 2012; Limesand, et al. 2006).

Fetal heart collection

Animals were euthanized by intravenous pentobarbital sodium (Fatal Plus, Bortech Pharmaceuticals, Dearborn, MI). The fetus was weighed, and the heart immediately excised. Blood was flushed from fetal hearts with a heparin-containing Tyrodes solution (Jonker, et al. 2007). As the high-pressure pumping chambers, we focused on the ventricles. Mid-ventricular biopsies were excised and frozen, and wound edges were sealed with cyanoacrylate. Hearts were enzymatically dissociated and cells were fixed with formaldehyde as previously described (Jonker et al. 2007). As ventricular wall weight cannot be obtained from dissociated hearts, a contemporaneous groups of control and IUGR age-matched fetuses with similar physiological and physical parameters were used to obtain ventricular wall weights (Control n=9, IUGR n=13) as previously described (Jonker et al. 2007).

Cardiomyocyte measurements

Length and width measurements were obtained from random, non-repeating photomicrographs from no fewer than 90 isolated cardiomyocytes separately from each ventricular wall, as previously described (Jonker et al. 2007). A shape factor, measured from no fewer than 10 mononucleated and binucleated myocytes per fetal ventricular wall, was used to calculate myocyte volume from length and width measurements (Jonker et al. 2007).

The number of nuclei in at least 300 myocytes from each ventricular wall of each animal were tabulated to determine the fractions of mono-, bi-, and quadrinucleated cells.

Detection of anti-Ki-67 antibody binding (MIB-1, Dako, Carpinteria, CA, USA) was used to determine cell cycle activity from ~500 cells per ventricular wall per animal as previously described (Jonker et al. 2007).

Cardiac number myocyte quantification

Cardiomyocyte number was calculated as previously described (Jonker et al. 2015; Jonker et al. 2007), with minor modifications. The proportional relationship between ventricular wall weight and heart weight was derived from values measured from a subset of animals (Control, n=9; IUGR, n=13). This was used to calculate ventricular wall weights from total heart weight for each enzymatically dissociated heart. Wall weights were multiplied by the proportion of myocardium which is composed of myocytes (Smolich, et al. 1989), and divided by the specific gravity of 1.05g/ml, which was then divided by the proportionally-represented myocyte volumes (Jonker et al. 2015; Jonker et al. 2007) to yield myocyte number per wall. As there were not enough quadrinucleated cells to obtain morphometric measurements, and as they have been found previously to be twice the volume of binucleated cells (Jonker et al. 2015), they were included in calculations using twice the volume of binucleated cells.

RNA extraction and quantitative real time PCR analysis

Total RNA was isolated from myocardial biopsies, reverse transcribed and used in qPCR using the ΔΔCT method (Lightcycler 480 II; Roche Life Science, Indianapolis, IN) as previously described (Brown, et al. 2014; Soto et al. 2017). Genes for analysis were selected based on the KEGG pathway analysis for fetal sheep IUGR skeletal muscle previously published, in addition to some other key cell cycle regulators (Soto et al. 2017). Those primers for qPCR assays that were not published previously (Soto et al. 2017), are provided in Table 1. mRNA expression levels of reference genes did not vary by treatment or ventricular wall, therefore all experimental genes are expressed as a ratio with the equal-weighted average of the reference genes. mRNA levels are expressed relative to average LV control values.

Table 1.

Sequences of primers used for qPCR.

Forward Reverse
Cyclin A2 (CCNA2) CCTGCAAACTGCAAAGTTGAA GGTGAAGGTCCAGGAGACA
Cyclin D1 (CCND1) ACTACCTGGACCGCTTCCT TTGGAGAGGAAGTGCTCGAT
Cyclin D2 (CCND2) TCCTCTCGCCATCAATTACC TCCTGAGGCTTGATGGAGTT
Cyclin dependent kinase 4 (CDK4) ATTTCCTTCATGCCAACTGCA CCAACACTCCACATGTCCAC
Cyclin dependent kinase 6 (CDK6) GCATCGTGATCTAAAACCACA GAGTCCAATCACGTCCAAGA
Activator of S phase kinase (DBF4) ATCTGGGAGGGCGAGTTGAAGAAT TGAGGTGATGTGGTTTCCGCAGTA
Myeloid ecotropic viral integration site 1 homolog (Meis1) ATATCATGAGGGCGTGGCTG ATAGGTCCTGGTGCCCTGAT
Myeloid leukemia factor 2 (MLF2) CTCAGCATCACAGATGGCAA CATGTCGTTCATCATCCCAA
Cyclin-dependent kinase inhibitor 1A (p21) GAGGACCACTTGGACCTGT TCTGCGTTTGGAGTGGTAGA
Cyclin-dependent kinase inhibitor 1B (p27) GCTTGCCCGAGTTCTACTAC CATTTTCTTCTGTTCTGTTGGC
Ribosomal protein L32 (RPL32) AATCAAGCGGAACTGGCG GGCATTGGGATTGGTGATT
Ribosomal protein L37a (RPL37A) ACCAAGAAGGTCGGAATCGT GGCACCACCAGCTACTGTTT
Transcription factor Dp-1 (TFDP1) AGGTCTTCATCGACCAGAACCTCA TACCAATCACCACTTGCTGCGAGA
Protein Kinase C Inhibitor Protein-1 (YWHAZ) CAAACGCTTCACAAGCAGAGAGCA TGCTGTGACTGATCCACAATCCCT

Statistical analysis

Comparisons of blood parameters and necropsy weights were by Student’s unpaired t-test (Prism 6, GraphPad Software, San Diego, CA). Sex distribution was assessed using Chi square test. Treatment (Control, IUGR), ventricular wall (LV, septum, RV) and sex (male, female) were initially screened as main effects by Student’s unpaired t-test; although sex differences do sometimes emerge in fetal cardiac studies (Botting, et al. 2018; Lumbers, et al. 2009), no significant sex effect was found in this dataset, thus sex was not included in the final analysis. The effect of sex was not evaluated for mRNA gene expression due to limited sample size. Two-way analysis of variance (ANOVA) was used to determine the effects of treatment and ventricular wall on cardiomyocyte and mRNA parameters. When indicated by a significant interaction term, multiple comparisons were conducted with Holm-Sidak correction. Pearson’s correlation coefficients were calculated to explore relationships between circulating hormones and cardiomyocyte parameters in IUGR fetuses; if significant, linear regression was performed to determine if relationships were similar between Control and IUGR fetuses. If not different, regression relationships were determined for all fetuses pooled. P<0.05 was considered statistically significant.

RESULTS

Fetal physiological characteristics

Gestational age (Control 134.9±0.8, IUGR 134.2±1.2) and sex distribution (Control 50% male, IUGR 53% male) were not different between groups. Placental insufficiency reduced fetal arterial PO2, hemoglobin saturation, O2 content, and plasma glucose (Table 2). No changes were observed in pH, PCO2, total hemoglobin, or plasma lactate. IUGR reduced fetal arterial plasma insulin and IGF-1 levels, and increased cortisol and norepinephrine levels.

Table 2.

Arterial blood gas and chemistry in control and IUGR fetal sheep aged ~134 dGA.

Comparison of Means
Control
(n=8)
IUGR
(n=15)
P-Value
pH 7.35±0.02 7.35±0.02 ns
Hemoglobin (mmol L−1) 7.8±1.6 7.4±1.0 ns
PCO2 (mmHg) 50.7±2.8 51.5±2.2 ns
PO2 (mmHg) 19.8±1.6 14.8±2.8* 0.0002
O2 saturation (%) 47.6±5.9 30.7±10.9* 0.0006
O2 content (mmol L−1) 3.1±0.5 2.1±0.9* 0.0063
Glucose (mg dL−1) 21±5 14±4* 0.0019
Lactate (mmol L−1) 2.5±0.5 2.7±0.9 ns
Insulin (ng mL−1) 0.4±0.2 0.2±0.1* 0.0171
Cortisol (ng mL−1) 9.2±7.0 23.6±18.2* 0.0431
Norepinephrine (pg mL−1) 602±404 1,699±1,492* 0.0034
IGF-1 (ng mL−1) 125±37 54±33* 0.0001

Groups compared by Student’s t-test. Not significant (ns). Data are shown as mean±standard deviation.

Placental insufficiency reduced fetal body weight (Fig. 1A) and heart weight (Fig. 1B). The ratio of heart-to-body weight was not different, but tended to be lower in IUGR (P=0.0613; Fig. 1C). Because IUGR changed hormone levels, the relationship of heart weight with these factors was tested in IUGR fetuses and found to be correlated with IGF-1 (r=0.8497, P<0.0001) (Fig. 1D).

Figure 1. Body and heart weights in control and IUGR fetal sheep.

Figure 1.

A) Body weight, B) heart weight, and C) heart weight relative to body weight in Control (n=8) and IUGR (n=15) ~134 dGA fetuses. D) Following significant correlation within IUGR fetuses between circulating IGF-1 and heart weight, regressions on separate treatment groups were not found to be significantly different, and a single regression was fit between circulating IGF-1 levels and heart weight (Y=0.1262X+10.18, r2=0.77, P<0.0001). E) Ventricular wall weights, and F) wall weights relative to heart weight in Control (n=9) and IUGR (n=13) fetuses at ~134 dGA. Groups in panels A-C compared by Student’s t-test. Groups in panels D-E compared by 2-way ANOVA and Holm-Sidak test. Different from *Control, #RV, and †septum (P<0.05). Data are shown as mean±standard deviation.

Ventricular wall weights were reduced by IUGR (main effect, P<0.0001) and affected by anatomical location (main effect, P<0.0001), but there was no significant interaction between these terms (P=0.0619; Fig. 1E). Wall weights normalized to heart weight were affected by anatomical location only (P<0.0001) (Fig. 1F).

Cardiomyocyte growth and maturation

The interaction term between treatment and anatomical location of cell origin was not significant for any myocyte measurement.

IUGR reduced cell cycle activity expressed as a percentage of mononucleated myocytes (P=0.0191; Fig. 2A). Ventricular source did not affect cell cycle activity (P=0.0905). IUGR reduced the proportion of binucleated myocytes, an index of maturation (P=0.0383; Fig. 3B). Proportion quadrinucleated was not different between groups and was less than 1% of all cells (data not shown).

Figure 2. Cardiomyocyte cell cycle activity and maturation in control and IUGR fetal sheep.

Figure 2.

A) Cell cycle activity, as determined by Ki-67 protein labeling, in Control (n=8) and IUGR (RV and LV n=13; Septum n=14) fetuses at ~134 dGA. B) Cell immaturity, as indicated by proportion binucleate, in IUGR fetuses (LV n=15, RV and septum n=14) and Control fetuses (n=8). Groups compared by 2-way ANOVA and Holm-Sidak test. Different from *Control (P<0.05). Data are shown as mean±standard deviation.

Figure 3. Cardiomyocyte size in control and IUGR fetal sheep.

Figure 3.

A) Mononucleated myocyte length, B) width, and C) volume, and D) binucleated myocyte length, E) width, and F) volume in Control fetuses (n=8) and IUGR fetuses (LV n=15, RV and septum n=14) at ~134 dGA. Groups compared by 2-way ANOVA and Holm-Sidak test. Different from *Control, #RV, and †Septum (P<0.05). Data are shown as mean±standard deviation.

Mononucleated myocyte lengths were reduced by IUGR (P=0.0012) and were different across the ventricular walls (P=0.0012) (Fig. 3A). IUGR did not affect mononucleated width (P=0.0612), but ventricular origin did (P<0.0001; Fig. 3B). Mononucleated myocyte volumes were reduced by IUGR (P=0.009) and different across the ventricular walls (P<0.0001; Fig. 3C).

Binucleated myocyte lengths were reduced by IUGR (P=0.0108) and affected by ventricular origin (P<0.0001; Fig. 3D). Binucleated widths were not changed by IUGR, but were different across the ventricular walls (P<0.0001; Fig. 3E). IUGR reduced binucleated myocyte volumes (P=0.0196), which were also affected by ventricular origin (P<0.0001; (Fig. 3F).

Cardiomyocyte number was reduced by IUGR (P=0.0361) and different across the ventricular walls (P<0.0001; Fig. 4).

Figure 4. Myocyte number in Control and IUGR fetal sheep.

Figure 4.

A) Total myocyte number, and B) number of mononucleated myocytes in IUGR (LV n=15, RV and septum n=14) and Control fetuses (n=8) at ~134 dGA. Groups compared by 2-way ANOVA and Holm-Sidak test. Different from *Control, #RV, †Septum (P<0.05). Data are shown as mean±standard deviation.

Associations between circulating factors and myocyte parameters

Because IUGR changed circulating hormones, the correlation of cardiomyocyte growth parameters with these factors was tested in IUGR fetuses. IGF-1 levels in IUGR fetuses were correlated with myocyte number in the LV (r=0.6903, P=0.0044), septum (r=0.7388, P=0.0025), and RV (r=0.5682, P=0.034) (Fig. 5).

Figure 5. Circulating IGF-1 levels predict cardiomyocyte number in Control and IUGR fetal sheep.

Figure 5.

Following significant correlation within IUGR fetuses (P<0.05), regressions on separate treatment groups were found to be not significantly different, and a single regression was fit between circulating IGF-1 levels and A) RV myocyte number (Y=0.0006741X+0.1393, r2=0.1747, P=0.0529), B) septum myocyte number (Y=0.001819X+0.2649, r2=0.4092, P=0.0013), and C) LV myocyte number (Y=0.005212X+0.805, r2=0.3177; P=0.0051). Linear regression±95% confidence intervals are plotted with raw data.

Insulin levels in IUGR fetuses were correlated with LV binucleate length (r=0.5763, P=0.0245), RV binucleate length (r=0.5472, P=0.0429), RV binucleate width (r=0.6034, P=0.0223), and RV mononucleate length (r=0.5988, P=0.0237) (Fig. 6). There was a tendency for a correlation with septum binucleate length (r=0.5067, P=0.0644). It was determined that the slopes of the regressions binucleate length against insulin levels differed significantly between Control and IUGR fetuses for LV (P=0.0181), and that the regression for Control fetuses was not significant, therefore the relationship for the IUGR fetuses alone was determined.

Figure 6. Circulating insulin predict some cardiomyocyte dimensions in Control and IUGR fetal sheep.

Figure 6.

Following significant correlation within IUGR fetuses (P<0.05), regressions were found to be different by treatment for A) LV binucleate length, therefore the regression on insulin for IUGR fetuses is plotted (Y=25.41X+71.44, r2=0.3321, P=0.0245) (Control regression was not significant). Regressions for other parameters were not significantly different by treatment, and a single regression was fit between circulating insulin levels and B) RV binucleate length (Y=15.63X+80.57, r2=0.2883, P=0.01), C) RV binucleate width (Y=3.731X+13.46, r2=0.2631, P=0.0146), D) RV mononucleate length (Y=16.86X+58.18, r2=0.4327, P=0.0009). Linear regression±95% confidence intervals are plotted with raw data.

Log-transformed cortisol levels in IUGR fetuses were negatively correlated with LV binucleated width (r=−0.5312, P=0.0416), and RV binucleated length (r=−0.6427, P=0.132) (Fig. 7). There were tendencies for correlation with RV proportion binucleated (r=0.5291, P=0.0517), and negative correlation with RV binucleate width (r=−0.5297, P=0.0514).

Figure 7. Circulating cortisol predicts some cardiomyocyte dimensions in Control and IUGR fetal sheep.

Figure 7.

Following significant correlation within IUGR fetuses (P<0.05), regressions on separate treatment groups were found to be not significantly different, and a single regression was fit between circulating cortisol and A) LV binucleate width (Y=−1.604X+13.21, r2=0.2778, P=0.0098), and B) RV binucleate length (Y=−6.587X+91.76, r2=0.2031, P=0.0353). Linear regression±95% confidence intervals are plotted with raw data.

Log-transformed norepinephrine levels in IUGR fetuses were correlated with RV proportion binucleated (r=0.5507, P=0.0413), and septum (r=−0.6112, P=0.0202). There was a tendency for negative correlation with RV binucleate width (r=−0.4684, P=0.0912), and binucleate length in the septum (r=−0.5193, P=0.0570). Linear regression relationships for RV proportion binucleated were not different between Control and IUGR fetuses, but the regression relationship for all fetuses together was not significant. Linear regression relationships for septum proportion binucleated had different intercepts between Control and IUGR fetuses (P=0.0103), and the slope of the regression for the Control relationship was not different from zero.

Cardiac mRNA expression levels

Reference genes RPL32, RPL37A, and MLF2 did not vary with treatment or between ventricles (Table 3).

Table 3.

mRNA expression levels in control and IUGR fetal sheep LV and RV aged ~134 dGA.

Relative Expression Levels Interaction Main Effects
RV LV Treatment Ventricle
Control
(n=3)
IUGR
(n=7)
Control
(n=7)
IUGR
(n=13)
P-value P-value P-value
Reference genes
  RPL32 0.99±0.22 0.93±0.18 1.00±0.04 0.98±0.25 ns ns ns
  RPL37A 1.01±0.31 1.03±0.17 1.00±0.16 1.08±0.27 ns ns ns
  MLF2 1.03±0.15 1.05±0.24 1.00±0.18 0.92±0.28 ns ns ns
Cyclins
  Cyclin A2 1.28±0.55 0.67±0.23 1.00±0.51 0.57±0.23 ns 0.0014 ns
  Cyclin B1 1.98±1.18 0.74±0.23 1.00±0.44 0.67±0.33 0.0306
  Cyclin B2 1.61±0.88 0.74±0.26 1.00±0.27 0.72±0.23 ns 0.0006 0.0381
  Cyclin D1 1.15±0.16 1.16±0.22 1.00±0.23 1.13±0.34 ns ns ns
  Cyclin D2 1.87±0.24 1.50±0.30 1.00±0.20 1.02±0.16 0.043
  Cyclin E2 1.03±0.27 0.94±0.15 1.00±0.21 0.82±0.25 ns ns ns
Cyclin dependent kinases
  CDK1 1.37±0.57 0.86±0.29 1.00±0.35 0.62±0.37 ns 0.009 ns
  CDK4 1.02±0.13 1.10±0.21 1.00±0.15 0.94±0.19 ns ns ns
  CDK6 1.40±0.07 1.14±0.16 1.00±0.14 0.97±0.09 0.0345
Cyclin dependent kinase inhibitors
  CDKN2C (p18) 1.12±0.19 1.06±0.19 1.00±0.18 0.80±0.22 ns ns 0.0348
  CDKN1A (p21) 0.49±0.15 0.67±0.18 1.00±0.42 0.91±0.26 ns ns 0.0041
  CDKN1B (p27) 0.92±0.03 1.23±0.35 1.00±0.11 0.99±0.25 ns ns ns
Cell cycle effectors and checkpoint genes
  MCM6 0.97±0.21 0.99±0.15 1.00±0.20 0.87±0.19 ns ns ns
  PLK1 1.47±0.99 0.78±0.28 1.00±0.78 0.70±0.30 ns 0.0299 ns
  CDC20 1.26±0.56 0.84±0.22 1.00±0.34 0.74±0.22 ns 0.0101 ns
  MAD2 1.23±0.40 0.87±0.21 1.00±0.26 0.70±0.32 ns 0.0134 ns
  BUB1 2.20±1.49 0.48±0.51 1.00±0.69 0.38±0.48 ns 0.0004 0.0303
  ESPL1 1.00±0.56 0.70±0.30 1.00±0.63 0.54±0.18 ns 0.0251 ns
  CHK1 1.09±0.21 1.10±0.31 1.00±0.25 0.83±0.38 ns ns ns
  DBF4 1.50±0.47 0.79±0.14 1.00±0.36 0.83±0.29 0.0398
  YWHAZ 1.34±0.19 1.13±0.19 1.00±0.14 0.93±0.19 ns ns 0.0015
Transcription factors
  TFDP1 0.96±0.10 0.94±0.14 1.00±0.09 0.94±0.16 ns ns ns
  Meis1 1.21±0.11 1.04±0.32 1.00±0.19 1.07±0.28 ns ns ns

Groups compared by 2-way ANOVA.

*

Different from ipsilateral control by Holm-Sidak test (P<0.05). Data are shown as mean±standard deviation.

IUGR reduced expression of cyclin A2 and cyclin B2 (Table 3). Treatment interacted with ventricular source for cyclin B1 and cyclin D2; for both genes RV expression was lower in IUGR, while RV expression was greater than LV. RV expression was also greater than LV for cyclin B2. There was no effect of treatment or ventricle on cyclin D1 or cyclin E2 levels.

IUGR reduced ventricular CDK1 expression (Table 3). The interaction term was significant for CDK6; IUGR reduced CDK6 expression in the RV, and expression was greater in the RV than the LV. There was no effect of treatment or ventricle on CDK4 levels.

CDKN2C (p18) expression was greater in the RV than LV, while CDKN1A (p21) was lower in the RV (Table 3). There was no effect of treatment or ventricle on CDKN1B (p27) levels.

IUGR reduced expression of PLK1, CDC20, MAD2, BUB1B, and ESPL1 (Table 3). Treatment interacted with ventricular source for DBF4; IUGR reduced DBF4 expression in the RV, and RV expression was greater than LV. RV expression was also greater than LV for BUB1B, and YWHAZ. There was no effect of treatment or ventricle on CHK1.

There was no effect of treatment or ventricle on transcription factors TFDP1 or Meis1 (Table 3).

DISCUSSION

We found that near-term fetuses affected by chronic placental insufficiency and IUGR had smaller cardiomyocytes with reduced terminal differentiation and proliferation, and consequently a diminished myocyte complement in the heart. Impaired growth and maturation was found across all ventricular walls, and these differences all contribute to the smaller hearts found in IUGR fetuses. These changes were supported by reduced mRNA expression of cyclins and cell cycle effectors and checkpoint genes in IUGR hearts.

Comparison of the heart and skeletal muscle in IUGR

Although the work demanded of fetal skeletal muscle is less than that of cardiac muscle, both are types of striated muscle and cellular complements of both are mostly set by the time of birth (Bergmann, et al. 2015; Burrell et al. 2003; Jonker et al. 2015; Rowe and Goldspink 1969; Widdowson, et al. 1972). We found previously that skeletal muscle is lighter in IUGR fetuses, the cross-sectional area of the myofibers is smaller, and that there is less myoblast proliferation, yet the skeletal muscle maintains the pool of Pax7+ myoblasts with proliferative potential (Rozance et al. 2018; Soto et al. 2017; Yates et al. 2014). Our findings in this study are comparable, with lighter hearts in IUGR fetuses, smaller myocytes, lower indices of proliferation, and decreased maturation.

Life-long reduction in lean mass (Fall 2011) and cardiomyocyte number (Vranas, et al. 2017) suggests that no adaptive mechanism helps the IUGR newborn undergo adequate physiological “catch-up” of muscle growth. Nevertheless, in near-term IUGR skeletal muscle the pool of Pax7+ myoblasts with proliferative potential is not reduced, and in the heart the mononucleated population of cardiomyocytes capable of proliferating is increased, suggesting opportunity for therapeutic intervention. Indeed, cultured Pax7+ skeletal myoblasts from IUGR fetuses responded much more aggressively to proliferative signals than Control cells in vitro (Soto et al. 2017). As circulating insulin and IGF-1 concentrations are reduced, this suggests that an IGF-1 rescue strategy in IUGR could yield a rapid increase in myocyte endowment at term (Eremia, et al. 2007; Harding, et al. 1994; Soto et al. 2017; Sundgren, et al. 2003).

Pathway analysis in near-term IUGR skeletal muscle found decreased expression of clusters of genes related to cell cycle regulation (Soto et al. 2017). The most profoundly affected genes include G1 progression regulators cyclin E2 and p18, initiator of DNA replication MCM6, G2/M progression regulator PLK1, regulators of commitment to mitosis cyclin B1, cyclin B2 and CDK1, regulator of nuclear movement and chromosome separation CDC20, spindle assembly quality control molecule MAD2, spindle checkpoint regulator BUB1B, initiator of separation of sister chromatids in mitosis ESPL1, and DNA damage cell cycle arrestor CHK1. We found that many of those genes with reduced expression in skeletal muscle are also reduced in cardiac muscle, including PLK1, cyclin B1, cyclin B2, CDK1, CDC20, MAD2, BUB1B and ESPL1, supporting the parallels in response to in utero challenge between these two types of striated muscle despite differences in preferential nutrient delivery during IUGR.

Hormonal regulation of cardiac growth in IUGR

Hormonal regulation of growth might help explain similar growth and gene expression patterns in IUGR skeletal muscle and heart despite preservation of nutrient delivery to the myocardium. In order to reduce the rate of spurious findings, we screened cardiac growth parameters against circulating hormone concentrations by performing correlations only within IUGR fetuses, followed up by testing whether regressions between Control and IUGR fetuses were different and, if they were not, performing regression on pooled fetal parameters. These results do not show causality, but indicated potential mechanisms regulating specific aspects of myocyte growth in the near-term fetal heart.

In IUGR fetuses, IGF-1 and insulin levels are half those in Control fetuses. IGF-1 is the main endocrine driver of fetal growth (Hellstrom, et al. 2016; Murray and Clayton 2013), is critical to skeletal muscle growth in development (Liu, et al. 1993; Mavalli, et al. 2010), and is a profound stimulus of cardiomyocyte proliferation in the fetal heart (Sundgren et al. 2003). Fetal heart weight and cardiomyocyte numbers were predicted by circulating IGF-1 levels. Circulating insulin levels predicted most myocyte length dimensions as well as one width dimension. Consequently, IGF-1 and/or insulin receptors might be therapeutic targets for treatment to increase fetal myocyte replication.

In contrast to IGF-1 and insulin, cortisol and norepinephrine levels are more than doubled in near-term IUGR fetuses. In fetal cardiomyocytes, cortisol has been linked to proliferation (Feng, et al. 2013; Giraud, et al. 2006; Reini, et al. 2008) and enlargement (Lumbers, et al. 2005), but also to apoptosis (Feng et al. 2013; Reini et al. 2008). However, cortisol reduced myoblast proliferation and causes myotube atrophy through decreased protein synthesis and increased protein degradation (Morgan, et al. 2016). Cortisol in fetal skeletal muscle suppresses IGF-1 expression (Li, et al. 2002), but not IGF-1 receptor 1 expression (Jellyman, et al. 2012), and IGF-1 opposes the effects of cortisol on skeletal muscle (Glass 2010; Morgan et al. 2016). Circulating cortisol levels negatively predicted two binucleated myocyte dimension parameters, supporting a role of growth repression in the heart. How cortisol interacts with low levels of IGF-1 to suppress growth or induce apoptosis in IUGR skeletal and cardiac muscle remains to be determined.

Norepinephrine is a non-selective adrenergic agonist linked to hypertrophy in adult cardiomyocytes. Phenylephrine, a selective α-adrenergic agonist, strongly stimulates hypertrophy in fetal sheep cardiomyocytes. It is notable that we found a reduction in cardiomyocyte size in IUGR fetuses concurrent with elevated norepinephrine, which suggests that cardiac adrenergic signaling is altered in IUGR or that there is a mechanism actively repressing fetal cardiomyocyte growth during placental restriction. Indeed, high circulating fetal norepinephrine inhibits overall fetal growth (Bassett and Hanson 1998; Milley 1997).

Interpretation of cardiac effects of IUGR

Body and heart weight were reduced in this study, as is common in models of placental restriction (Louey et al. 2007; Morrison et al. 2007; Tare et al. 2014). Reduction in heart weight relative to body weight, towards which there was a tendency in this study, has been found in carunclectomy-induced IUGR (Bubb et al. 2007). The carunculectomy model is created by surgical excision of placental implantation sites in ewes prior to breeding, which induces a progressive phenotype from early in gestation similar to the environmental model used in this study. This contrasts with fetoplacental embolization, induced in the last third of gestation, in which heart weight relative to body weight is unchanged (Louey et al. 2007) or increased (Murotsuki et al. 1997).

The relative contributions of small myocyte size, inhibited proliferation, and less terminal differentiation to overall cardiac undergrowth in IUGR can be estimated by calculating the loss in mass attributable to each difference. Reduced heart weight is due to smaller myocyte size (~30-55%), reduced myocyte number (~20-40%), changes in non-myocyte components (~20%), and reduced terminal differentiation (~5-10%; because binucleated cells are larger than mononucleated cells). Reduced proliferation and maturation is common to humans affected by placental insufficiency and animal models of IUGR (Botting et al. 2014; Bubb et al. 2007; Louey et al. 2007; Mayhew et al. 1999; Morrison et al. 2007; Murotsuki et al. 1997; Takahashi et al. 1995).

Although diminished cellular volume due shorter myocytes in IUGR was the largest contributor to reduced heart weight in this study, there is disagreement among other studies about the role of retarded myocyte enlargement in IUGR hearts. One study in carunclectomized ewes indicates that IUGR reduces mononucleated myocyte length and width, but only binucleated width near term (Morrison et al. 2007), however, these results are confounded by the finding that control binucleated myocytes shrink in length and width over the period of 132-141 dGA. In contrast, no differences in myocyte dimensions have been found in fetoplacental embolization models, which are initiated in the last third of gestation (Bubb et al. 2007; Louey et al. 2007). It may be that the effect of IUGR on cardiomyocyte size occurs over a long period and is only detectable when placental insufficiency is initiated early in gestation.

Differences between LV and RV myocytes

Due to hemodynamic shunts, both fetal ventricles pump against similar pressure into the systemic circulation and are more alike in mass and geometry in the fetus than at any later age. Despite these similarities, fetal myocyte appear to have a ventricular “identity”: RV cardiomyocytes are larger and less numerous than LV myocytes (Burrell et al. 2003; Jonker et al. 2007). Although these differences were found in this study, the changes induced by IUGR did not vary by ventricular wall, consistent with other studies (Bubb et al. 2007; Jonker, et al. 2011; Segar, et al. 2013). Relationships shown between circulating hormones and myocyte parameters that are significant only in one ventricle should not be taken as proof of a ventricular “identity”, as causative effects of hormones has not been established in this study. The basis of the apparent ventricular “identity” remains unknown.

Strengths and limitations of the study

The ovine model of chronic and progressive placental insufficiency used in this study shares many phenotypic characteristics with human placental insufficiency, including similar patterns of heart and brain sparing, lower rates of amino acid, glucose, and oxygen transfer from mother to the fetus, reduced circulating growth factors, and elevated catecholamines (Barry et al. 2008). This model also allowed for chronic catheterization of the fetal circulation for fetal blood sampling concurrent with cardiac tissue collection, to correlate in vivo physiological measures with comprehensive morphometric data. Further, cardiomyocytes from left, right and septal ventricular walls were isolated after heart dissociation, which allowed for ventricular-specific comparisons of cardiomyocyte number, maturity, and size. However, we were not adequately powered to assess sex differences for all measurements in this study, despite reports of sexual dimorphism in cardiomyocyte number related to IUGR (Botting et al. 2018). Further, tissue availability limited further evaluation of downstream signaling activation by insulin and IGF-1.

Conclusions

IUGR fetuses had low circulating insulin and IGF-1 levels, high circulating cortisol levels, and light bodies and hearts. IUGR cardiomyocytes were smaller, less mature, less active in the cell cycle, and less numerous than Control cells, and there was down-regulation of cell cycle genes in IUGR hearts. We did not find differences in heart size and cardiomyocyte indices attributable to fetal sex, therefore sex as a main effect was not included in the final model. Interactions between sex and treatment could not be fully evaluated due to small sample size and should be pursued in future studies. Similarities between heart and skeletal muscle in IUGR leading to reductions in myocyte cell cycle activity, number, size and maturation suggest similarities in regulation of growth, perhaps through IGF-1 and insulin signaling, despite differences in nutrient delivery prioritization. Further studies are required to understand the potential of fetal anabolic hormones such as insulin and IGF-1 as therapeutic agents to increase myocyte number in hearts of IUGR fetuses.

ACKNOWLEDGEMENTS

We thank Samantha Louey for critical review of the manuscript.

FUNDING

This work was supported by NIH Grants K12 HD057022, R01 HD079404, and The Center for Women’s Health Research, University of Colorado School of Medicine (LDB), and R01 HD071068 (SSJ).

Footnotes

DECLARATION OF INTEREST

The authors have nothing to declare.

REFERENCES

  1. Adler CP, Friedburg H, Herget GW, Neuburger M & Schwalb H 1996. Variability of cardiomyocyte DNA content, ploidy level and nuclear number in mammalian hearts. Virchows Archiv 429 159–164. [DOI] [PubMed] [Google Scholar]
  2. Alexander BT, Dasinger JH & Intapad S 2015. Fetal programming and cardiovascular pathology. Compr Physiol 5 997–1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barker DJ & Thornburg KL 2013. The obstetric origins of health for a lifetime. Clin Obstet Gynecol 56 511–519. [DOI] [PubMed] [Google Scholar]
  4. Barry JS, Rozance PJ & Anthony RV 2008. An animal model of placental insufficiency-induced intrauterine growth restriction. Semin Perinatol 32 225–230. [DOI] [PubMed] [Google Scholar]
  5. Baschat AA & Hecher K 2004. Fetal growth restriction due to placental disease. Semin Perinatol 28 67–80. [DOI] [PubMed] [Google Scholar]
  6. Bassett JM & Hanson C 1998. Catecholamines inhibit growth in fetal sheep in the absence of hypoxemia. Am J Physiol 274 R1536–1545. [DOI] [PubMed] [Google Scholar]
  7. Bell AW, Wilkening RB & Meschia G 1987. Some aspects of placental function in chronically heat-stressed ewes. J Dev Physiol 9 17–29. [PubMed] [Google Scholar]
  8. Bellotti M, Pennati G, De Gasperi C, Bozzo M, Battaglia FC & Ferrazzi E 2004. Simultaneous measurements of umbilical venous, fetal hepatic, and ductus venosus blood flow in growth-restricted human fetuses. Am J Obstet Gynecol 190 1347–1358. [DOI] [PubMed] [Google Scholar]
  9. Bergmann O, Zdunek S, Felker A, Salehpour M, Alkass K, Bernard S, Sjostrom SL, Szewczykowska M, Jackowska T, Dos Remedios C, et al. 2015. Dynamics of Cell Generation and Turnover in the Human Heart. Cell 161 1566–1575. [DOI] [PubMed] [Google Scholar]
  10. Botting KJ, Loke XY, Zhang S, Andersen JB, Nyengaard JR & Morrison JL 2018. IUGR decreases cardiomyocyte endowment and alters cardiac metabolism in a sex- and cause-of-IUGR-specific manner. Am J Physiol Regul Integr Comp Physiol 315 R48–R67. [DOI] [PubMed] [Google Scholar]
  11. Botting KJ, McMillen IC, Forbes H, Nyengaard JR & Morrison JL 2014. Chronic hypoxemia in late gestation decreases cardiomyocyte number but does not change expression of hypoxia-responsive genes. J Am Heart Assoc 3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Brown LD & Hay WW, Jr. 2016. Impact of placental insufficiency on fetal skeletal muscle growth. Mol Cell Endocrinol 435 69–77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Brown LD, Rozance PJ, Thorn SR, Friedman JE & Hay WW Jr. 2012. Acute supplementation of amino acids increases net protein accretion in IUGR fetal sheep. Am J Physiol Endocrinol Metab 303 E352–364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Brown LD, Thorn SR, O’Meara MC, Lavezzi JR & Rozance PJ 2014. A physiological increase in insulin suppresses muscle-specific ubiquitin ligase gene activation in fetal sheep with sustained hypoglycemia. Physiol Rep 2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Bubb KJ, Cock ML, Black MJ, Dodic M, Boon WM, Parkington HC, Harding R & Tare M 2007. Intrauterine growth restriction delays cardiomyocyte maturation and alters coronary artery function in the fetal sheep. J Physiol 578 871–881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Burrell JH, Boyn AM, Kumarasamy V, Hsieh A, Head SI & Lumbers ER 2003. Growth and maturation of cardiac myocytes in fetal sheep in the second half of gestation. Anat Rec A Discov Mol Cell Evol Biol 274 952–961. [DOI] [PubMed] [Google Scholar]
  17. Camm EJ, Brain KL, Niu Y, Allison BJ, Botting KJ, Itani N, Skeffington KL, Beck C & Giussani DA 2015. Chronic fetal hypoxia in ovine pregnancy triggers a fetal origin of heart disease that amplifies with ageing: prevention with maternal antioxidant treatment (abstract). Reprod Sci 22 1. [Google Scholar]
  18. Clubb FJ Jr. & Bishop SP 1984. Formation of binucleated myocardial cells in the neonatal rat. An index for growth hypertrophy. Laboratory Investigation 50 571–577. [PubMed] [Google Scholar]
  19. Culpepper C, Wesolowski SR, Benjamin J, Bruce JL, Brown LD, Jonker SS, Wilkening RB, Hay WW Jr & Rozance PJ 2016. Chronic anemic hypoxemia increases plasma glucagon and hepatic PCK1 mRNA in late-gestation fetal sheep. Am J Physiol Regul Integr Comp Physiol 311 R200–208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. de Boo HA & Harding JE 2006. The developmental origins of adult disease (Barker) hypothesis. Aust N Z J Obstet Gynaecol 46 4–14. [DOI] [PubMed] [Google Scholar]
  21. Eremia SC, de Boo HA, Bloomfield FH, Oliver MH & Harding JE 2007. Fetal and amniotic insulin-like growth factor-I supplements improve growth rate in intrauterine growth restriction fetal sheep. Endocrinology 148 2963–2972. [DOI] [PubMed] [Google Scholar]
  22. Fall CH 2011. Evidence for the intra-uterine programming of adiposity in later life. Ann Hum Biol 38 410–428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Feng X, Reini SA, Richards E, Wood CE & Keller-Wood M 2013. Cortisol stimulates proliferation and apoptosis in the late gestation fetal heart: differential effects of mineralocorticoid and glucocorticoid receptors. Am J Physiol Regul Integr Comp Physiol 305 R343–350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Fernandez-Twinn DS & Ozanne SE 2010. Early life nutrition and metabolic programming. Ann N Y Acad Sci 1212 78–96. [DOI] [PubMed] [Google Scholar]
  25. Giraud GD, Louey S, Jonker S, Schultz J & Thornburg KL 2006. Cortisol stimulates cell cycle activity in the cardiomyocyte of the sheep fetus. Endocrinology 147 3643–3649. [DOI] [PubMed] [Google Scholar]
  26. Glass DJ 2010. Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care 13 225–229. [DOI] [PubMed] [Google Scholar]
  27. Harding JE, Liu L, Evans PC & Gluckman PD 1994. Insulin-like growth factor 1 alters feto-placental protein and carbohydrate metabolism in fetal sheep. Endocrinology 134 1509–1514. [DOI] [PubMed] [Google Scholar]
  28. Hellstrom A, Ley D, Hansen-Pupp I, Hallberg B, Lofqvist C, van Marter L, van Weissenbruch M, Ramenghi LA, Beardsall K, Dunger D, et al. 2016. Insulin-like growth factor 1 has multisystem effects on foetal and preterm infant development. Acta Paediatr 105 576–586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Huttenbach Y, Ostrowski ML, Thaller D & Kim HS 2001. Cell proliferation in the growing human heart: MIB-1 immunostaining in preterm and term infants at autopsy. Cardiovasc Pathol 10 119–123. [DOI] [PubMed] [Google Scholar]
  30. Jellyman JK, Martin-Gronert MS, Cripps RL, Giussani DA, Ozanne SE, Shen QW, Du M, Fowden AL & Forhead AJ 2012. Effects of cortisol and dexamethasone on insulin signalling pathways in skeletal muscle of the ovine fetus during late gestation. PLoS One 7 e52363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Jonker SS, Louey S, Giraud GD, Thornburg KL & Faber JJ 2015. Timing of cardiomyocyte growth, maturation, and attrition in perinatal sheep. FASEB J 29 4346–4357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Jonker SS, Scholz TD & Segar JL 2011. The effect of adrenalectomy on the cardiac response to subacute fetal anemia. Can J Physiol Pharmacol 89 79–88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Jonker SS, Zhang L, Louey S, Giraud GD, Thornburg KL & Faber JJ 2007. Myocyte enlargement, differentiation, and proliferation kinetics in the fetal sheep heart. J Appl Physiol (1985) 102 1130–1142. [DOI] [PubMed] [Google Scholar]
  34. Kim HD, Kim DJ, Lee IJ, Rah BJ, Sawa Y & Schaper J 1992. Human fetal heart development after mid-term: morphometry and ultrastructural study. J Mol Cell Cardiol 24 949–965. [DOI] [PubMed] [Google Scholar]
  35. Li J, Forhead AJ, Dauncey MJ, Gilmour RS & Fowden AL 2002. Control of growth hormone receptor and insulin-like growth factor-I expression by cortisol in ovine fetal skeletal muscle. J Physiol 541 581–589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Limesand SW, Rozance PJ, Smith D & Hay WW Jr. 2007. Increased insulin sensitivity and maintenance of glucose utilization rates in fetal sheep with placental insufficiency and intrauterine growth restriction. Am J Physiol Endocrinol Metab 293 E1716–1725. [DOI] [PubMed] [Google Scholar]
  37. Limesand SW, Rozance PJ, Zerbe GO, Hutton JC & Hay WW Jr. 2006. Attenuated insulin release and storage in fetal sheep pancreatic islets with intrauterine growth restriction. Endocrinology 147 1488–1497. [DOI] [PubMed] [Google Scholar]
  38. Liu JP, Baker J, Perkins AS, Robertson EJ & Efstratiadis A 1993. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75 59–72. [PubMed] [Google Scholar]
  39. Louey S, Jonker SS, Giraud GD & Thornburg KL 2007. Placental insufficiency decreases cell cycle activity and terminal maturation in fetal sheep cardiomyocytes. J Physiol 580 639–648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Lumbers ER, Boyce AC, Joulianos G, Kumarasamy V, Barner E, Segar JL & Burrell JH 2005. Effects of cortisol on cardiac myocytes and on expression of cardiac genes in fetal sheep. Am J Physiol Regul Integr Comp Physiol 288 R567–574. [DOI] [PubMed] [Google Scholar]
  41. Lumbers ER, Kim MY, Burrell JH, Kumarasamy V, Boyce AC, Gibson KJ, Gatford KL & Owens JA 2009. Effects of intrafetal IGF-I on growth of cardiac myocytes in late-gestation fetal sheep. Am J Physiol Endocrinol Metab 296 E513–519. [DOI] [PubMed] [Google Scholar]
  42. Marconi AM & Paolini CL 2008. Nutrient transport across the intrauterine growth-restricted placenta. Semin Perinatol 32 178–181. [DOI] [PubMed] [Google Scholar]
  43. Mavalli MD, DiGirolamo DJ, Fan Y, Riddle RC, Campbell KS, van Groen T, Frank SJ, Sperling MA, Esser KA, Bamman MM, et al. 2010. Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice. J Clin Invest 120 4007–4020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Mayhew TM, Gregson C & Fagan DG 1999. Ventricular myocardium in control and growth-retarded human fetuses: growth in different tissue compartments and variation with fetal weight, gestational age, and ventricle size. Hum Pathol 30 655–660. [DOI] [PubMed] [Google Scholar]
  45. Milley JR 1997. Ovine fetal metabolism during norepinephrine infusion. Am J Physiol 273 E336–347. [DOI] [PubMed] [Google Scholar]
  46. Morgan SA, Hassan-Smith ZK, Doig CL, Sherlock M, Stewart PM & Lavery GG 2016. Glucocorticoids and 11beta-HSD1 are major regulators of intramyocellular protein metabolism. J Endocrinol 229 277–286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Morrison JL, Botting KJ, Dyer JL, Williams SJ, Thornburg KL & McMillen IC 2007. Restriction of placental function alters heart development in the sheep fetus. Am J Physiol Regul Integr Comp Physiol 293 R306–313. [DOI] [PubMed] [Google Scholar]
  48. Murotsuki J, Challis JR, Han VK, Fraher LJ & Gagnon R 1997. Chronic fetal placental embolization and hypoxemia cause hypertension and myocardial hypertrophy in fetal sheep. Am J Physiol 272 R201–207. [DOI] [PubMed] [Google Scholar]
  49. Murray PG & Clayton PE 2013. Endocrine control of growth. Am J Med Genet C Semin Med Genet 163C 76–85. [DOI] [PubMed] [Google Scholar]
  50. Phillips DI, Barker DJ, Hales CN, Hirst S & Osmond C 1994. Thinness at birth and insulin resistance in adult life. Diabetologia 37 150–154. [DOI] [PubMed] [Google Scholar]
  51. Poudel R, McMillen IC, Dunn SL, Zhang S & Morrison JL 2015. Impact of chronic hypoxemia on blood flow to the brain, heart, and adrenal gland in the late-gestation IUGR sheep fetus. Am J Physiol Regul Integr Comp Physiol 308 R151–162. [DOI] [PubMed] [Google Scholar]
  52. Regnault TR, de Vrijer B, Galan HL, Wilkening RB, Battaglia FC & Meschia G 2007. Development and mechanisms of fetal hypoxia in severe fetal growth restriction. Placenta 28 714–723. [DOI] [PubMed] [Google Scholar]
  53. Reini SA, Dutta G, Wood CE & Keller-Wood M 2008. Cardiac corticosteroid receptors mediate the enlargement of the ovine fetal heart induced by chronic increases in maternal cortisol. J Endocrinol 198 419–427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Rowe RW & Goldspink G 1969. Muscle fibre growth in five different muscles in both sexes of mice. J Anat 104 519–530. [PMC free article] [PubMed] [Google Scholar]
  55. Rozance PJ, Zastoupil L, Wesolowski SR, Goldstrohm DA, Strahan B, Cree-Green M, Sheffield-Moore M, Meschia G, Hay WW, Jr., Wilkening RB, et al. 2018. Skeletal muscle protein accretion rates and hindlimb growth are reduced in late gestation intrauterine growth-restricted fetal sheep. J Physiol 596 67–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Segar JL, Volk KA, Lipman MH & Scholz TD 2013. Thyroid hormone is required for growth adaptation to pressure load in the ovine fetal heart. Exp Physiol 98 722–733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Smolich JJ, Walker AM, Campbell GR & Adamson TM 1989. Left and right ventricular myocardial morphometry in fetal, neonatal, and adult sheep. Am J Physiol 257 H1–9. [DOI] [PubMed] [Google Scholar]
  58. Soto SM, Blake AC, Wesolowski SR, Rozance PJ, Barthel KB, Gao B, Hetrick B, McCurdy CE, Garza NG, Hay WW, Jr., et al. 2017. Myoblast replication is reduced in the IUGR fetus despite maintained proliferative capacity in vitro. J Endocrinol 232 475–491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Sundgren NC, Giraud GD, Schultz JM, Lasarev MR, Stork PJ & Thornburg KL 2003. Extracellular signal-regulated kinase and phosphoinositol-3 kinase mediate IGF-1 induced proliferation of fetal sheep cardiomyocytes. Am J Physiol Regul Integr Comp Physiol 285 R1481–1489. [DOI] [PubMed] [Google Scholar]
  60. Takahashi N, Nishida H, Arai T & Kaneda Y 1995. Abnormal cardiac histology in severe intrauterine growth retardation infants. Acta Paediatr Jpn 37 341–346. [DOI] [PubMed] [Google Scholar]
  61. Tare M, Parkington HC, Wallace EM, Sutherland AE, Lim R, Yawno T, Coleman HA, Jenkin G & Miller SL 2014. Maternal melatonin administration mitigates coronary stiffness and endothelial dysfunction, and improves heart resilience to insult in growth restricted lambs. J Physiol 592 2695–2709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Thureen PJ, Trembler KA, Meschia G, Makowski EL & Wilkening RB 1992. Placental glucose transport in heat-induced fetal growth retardation. Am J Physiol 263 R578–585. [DOI] [PubMed] [Google Scholar]
  63. Vranas S, Heinemann GK, Liu H, De Blasio MJ, Owens JA, Gatford KL & Black MJ 2017. Small size at birth predicts decreased cardiomyocyte number in the adult ovine heart. J Dev Orig Health Dis 8 618–625. [DOI] [PubMed] [Google Scholar]
  64. Widdowson EM, Crabb DE & Milner RD 1972. Cellular development of some human organs before birth. Arch Dis Child 47 652–655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Yates DT, Clarke DS, Macko AR, Anderson MJ, Shelton LA, Nearing M, Allen RE, Rhoads RP & Limesand SW 2014. Myoblasts from intrauterine growth-restricted sheep fetuses exhibit intrinsic deficiencies in proliferation that contribute to smaller semitendinosus myofibres. J Physiol 592 3113–3125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Zak R 1974. Development and proliferative capacity of cardiac muscle cells. Circ Res 35 suppl II: 17–26. [PubMed] [Google Scholar]

RESOURCES